Mitsubishi Tanabe Pharma America Announces Presentations in ALS at 2023 MDA Clinical & Scientific Conference

Mitsubishi Tanabe Pharma America (MTPA) has declared that it will be participating in the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference with several presentations related to amyotrophic lateral sclerosis (ALS).

The event, which is scheduled to be held on May 19-21, 2023 in Orlando, Florida, will feature presentations from MTPA’s clinical and research teams concerning the company’s latest findings on ALS treatments.

In particular, MTPA will present data related to its investigational compound, edaravone, which has been shown in clinical trials to reduce the rate of functional decline in ALS patients.

MTPA’s clinical development team will also present data on the company’s clinical trial program, which includes both Phase 3 and open-label clinical trials.

The MDA Clinical & Scientific Conference is the premier gathering of ALS researchers, clinicians, and advocates from around the world.

At the conference, MTPA will have an exhibit booth to provide attendees with information about its research and clinical programs, as well as its ongoing commitment to ALS patients.

MTPA President and CEO, Stephen H. DeWitt, commented on the company’s participation in the conference.

“We are delighted to have the opportunity to share our latest research and clinical findings with the ALS community at the 2023 MDA Clinical & Scientific Conference,” said DeWitt.

“We look forward to engaging with researchers and clinicians, and to furthering our commitment to improving the lives of people living with ALS.”

MTPA’s participation in the 2023 MDA Clinical & Scientific Conference marks the company’s ongoing dedication to developing potential treatments for ALS and other neuromuscular diseases.

With the event scheduled to take place in less than two years, the company is poised to make a lasting impact in the ALS community with its ongoing research and clinical programs.

MTPA’s participation in the 2023 MDA Clinical & Scientific Conference reflects its commitment to applying cutting-edge scientific research to develop treatments that improve the lives of ALS patients.

The company’s presentations at the conference will provide a valuable opportunity to share its findings with the global ALS community and to further its mission of developing treatments that can improve the lives of people living with ALS.